Clinical Trial

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-01-06; most recent amendment 2026-05-01.
Status change: Recruiting → Active, Not Recruiting 2026-05-01
Trial Details
NCT Number NCT06768671
Lead Sponsor MoonLake Immunotherapeutics AG
Conditions Hidradenitis Suppurativa
Enrollment 35 participants
Start Date 2024-12-30
Primary Completion 2026-09-28 (estimated)
Study Completion 2026-09-28 (estimated)
Updated on ClinicalTrials.gov 2026-05-06